Nanobiotix (NBTX)

Executive Summary

Nanobiotix is a late-stage clinical biotechnology company pioneering nanoparticle-based therapies to enhance radiotherapy. Its lead product candidate, NBTXR3, consists of hafnium oxide nanoparticles injected directly into tumors and activated by standard radiotherapy, increasing radiation dose within cancer cells while sparing healthy tissue. The company is advancing NBTXR3 across multiple solid tumor indications, with a pivotal Phase 2/3 trial in head and neck squamous cell carcinoma (HNSCC) being the most advanced. Nanobiotix has a global collaboration with Johnson & Johnson's Janssen for development and commercialization. Financially, the company is publicly traded (Euronext: NBTX) with a market capitalization around $1.85 billion. Recent pipeline updates include a newly initiated Phase 1/2 trial in locally-advanced non-small cell lung cancer (NSCLC) and an ongoing Phase 1 combination study with immune checkpoint inhibitors. The company's platform offers a unique physical mechanism distinct from traditional biologics, positioning it as a potential standard-of-care enhancer in radio-oncology.

Upcoming Catalysts (preview)

• H2 2026Pivotal Phase 2/3 data readout for NBTXR3 in head and neck cancer60% success
• H1 2027Initiation of Phase 3 trial for NBTXR3 in additional indication (e.g., lung or liver cancer)50% success
• H2 2026Regulatory submission or milestone from Janssen collaboration40% success